The Bibliometrics-based Genomics Studies on Prognosis of Ischemic Cerebrovascular Disease

doi:10.3969/j.issn.1673-5765.2023.03.005

Abstract

Abstract: Objective To analyze the current research status, hotspots, and frontier fields of genomics studies on the prognosis of ischemic cerebrovascular disease (ICVD) from 2017 to 2022.
Methods The related English literature of genomics in the field of ICVD was retrieved in the Web of Science Core Collection (SCI-EXPANDED) from January 1, 2017 to October 1, 2022. CiteSpace software was used to analyze the cooperation network among the publishing countries, institutions and authors; the co-citation network of reference, first author of reference and journals; clustering results of references; the co-occurrence network of keywords and their clustering results. The results were presented by visual maps.
Results A total of 353 papers were included in this study. China ranked the first in the world with 144 articles, but only with five countries with cooperation partnership. Capital Medical University was the most prolific institution, with 20 articles. Six of the top ten authors were from members of the International Stroke Genetics Consortium (ISGC) , who were the main contributors and formed major cooperation clusters. Genome-wide association analysis (GWAS) and Mendelian randomization were the most commonly used research methods. In recent years, the hotspots focused on exploring the common genetic pathways of stroke prognosis and other complex diseases, genetic variation affecting the efficacy of antiplatelet drugs, and the influence of inflammatory mechanism on prognosis.
Conclusions The genomics studies of ICVD prognosis, which explore the underlying mechanism to facilitate new drugs development, have gained the popularity year by year and formed several research hotspots.

Key words: Ischemic cerebrovascular disease; Prognosis; Genomics; Bibliometrics

摘要： 目的分析2017—2022年缺血性脑血管病（ischemic cerebrovascular disease，ICVD）预后的基因组学研究现状、研究热点及前沿领域。
方法在Web of Science核心合集（SCI-EXPANDED）中检索2017年1月1日—2022年10月1日ICVD预后的基因组学相关文献。使用CiteSpace软件分析文献中发文国家、机构、作者间的合作网络；参考文献、参考文献第一作者、期刊的共被引网络；参考文献的聚类结果；关键词的共现网络及其聚类结果，并使用可视化图谱呈现结果。
结果共纳入353篇文献。中国发文144篇，居全球首位，但仅与5个国家建立了合作关系。首都医科大学是发文最多的机构，共20篇。国际卒中遗传学联盟成员在发文量前10位的作者中占据6位，是发文的主力军并形成了主要的合作团簇。研究方法多使用全基因组关联分析和孟德尔随机化。近年来的研究热点是探究卒中预后与其他复杂疾病的共同遗传通路、影响抗血小板药物疗效的遗传变异，以及炎症机制在预后中的影响。
结论 ICVD预后的基因组学研究热度逐年上升，已形成多个研究热点，主要探索相关潜在机制来推动新药研发。

关键词: 缺血性脑血管病; 预后; 基因组学; 文献计量学

GOU Lan, XU Zhe, LI Lanxin, SHI Yanfeng, LIU Yang, ZHAO Manman, LI Hao, CHENG Si. The Bibliometrics-based Genomics Studies on Prognosis of Ischemic Cerebrovascular Disease[J]. Chinese Journal of Stroke, 2023, 18(03): 266-272.

勾岚, 许喆, 李兰欣, 石延枫, 刘阳, 赵曼曼, 李昊, 程丝. 基于文献计量学分析缺血性脑血管病预后的基因组学研究[J]. 中国卒中杂志, 2023, 18(03): 266-272.

References

[1] GBD 2019 Stroke Collaborators. Global，regional，and national burden of stroke and its risk factors，1990–2019：a systematic analysis for the global burden of disease study 2019[J]. Lancet Neurol，2021，20（10）：795-820.
[2] 王拥军，李子孝，谷鸿秋，等. 中国卒中报告2020（中文版）（1）[J]. 中国卒中杂志，2022，17（5）：433-447.
[3] 周梦圆，陈玮琪，荆京，等. 非致残性缺血性脑血管事件的流行病学及预后[J]. 中国卒中杂志，2018，13（5）：473-476.
[4] WANG Y J. Residual recurrence risk of ischaemic cerebrovascular events：concept，classification and implications[J]. Stroke Vasc Neurol，2021，6（2）：155-157.
[5] LEE J M，FERNANDEZ-CADENAS I，LINDGREN A G. Using human genetics to understand mechanisms in ischemic stroke outcome：from early brain injury to long-term recovery[J]. Stroke，2021，52（9）：3013-3024.
[6] 许喆，程丝，刘阳，等. 脑血管病基因组学数据分析流程建设[J]. 中国卒中杂志，2022，17（3）：217-226.
[7] MONTANER J，RAMIRO L，SIMATS A，et al. Multilevel omics for the discovery of biomarkers and therapeutic targets for stroke[J]. Nat Rev Neurol，2020，16（5）：247-264.
[8] 李卫文. 改变世界的科学计划：人类基因组计划[J]. 生物学杂志，2001，18（2）：47-48.
[9] MALIK R，CHAUHAN G，TRAYLOR M，et al. Multiancestry genome-wide association study of 520，000 subjects identifies 32 loci associated with stroke and stroke subtypes [J]. Nat Genet，2018，50（4）：524-537.
[10] FLINT J，ESKIN E. Genome-wide association studies in mice[J]. Nat Rev Genet，2012，13（11）：807-817.
[11] UITTERLINDEN A G. An introduction to genome-wide association studies：GWAS for dummies[J]. Semin Reprod Med，2016，34（4）：196-204.
[12] DALE C E，FATEMIFAR G，PALMER T M，et al. Causal associations of adiposity and body fat distribution with coronary heart disease，stroke subtypes，and type 2 diabetes mellitus[J]. Circulation，2017，135（24）：2373-2388.
[13] VIRANI S S，ALONSO A，BENJAMIN E J，et al. Heart disease and stroke statistics-2020 update：a report from the American Heart Association[J/OL]. Circulation，2020，141（9）：e139-e596[2022-11-10]. https://doi.org/10.1161/CIR. 0000000000000757.
[14] DAVEY SMITH G，HEMANI G. Mendelian randomization：genetic anchors for causal inference in epidemiological studies[J/OL]. Hum Mol Genet，2014，23（R1）：R89-R98[2022-11-10]. https://doi.org/10.1093/hmg/ddu328.
[15] NIKOLIC D，JANKOVIC M，PETROVIC B，et al. Genetic aspects of inflammation and immune response in stroke[J/OL]. Int J Mol Sci，2020，21（19）：7409[2022-11-10]. https://doi.org/10.3390/ijms21197409.
[16] GROMADZKA G，SARZYNSKA-DLUGOSZ I，CZLONKOWSKA A. IL1RN intron 2 polymorphism caused by variable number tandem repeats is associated with 1-year outcome in patients with ischaemic stroke[J]. J Neurol Neurosurg Psychiatry，2007，78（2）：183-186.
[17] CHAKRABORTY B，CHOWDHURY D，VISHNOI G，et al. Interleukin-6 gene -174 G/C promoter polymorphism predicts severity and outcome in acute ischemic stroke patients from North India[J]. J Stroke Cerebrovasc Dis，2013，22（5）：683-689.
[18] MAROUSI S，ANTONACOPOULOU A，KALOFONOS H，et al. Functional inflammatory genotypes in ischemic stroke：could we use them to predict age of onset and long-term outcome?[J/OL]. Stroke Res Treat，2011，2011：792923[2022-11-10]. https://doi. org/10.4061/2011/792923.
[19] MAGUIRE J，THAKKINSTIAN A，LEVI C，et al. Impact of COX-2 rs5275 and rs20417 and GPIIIa rs5918 polymorphisms on 90-day ischemic stroke functional outcome：a novel finding[J]. J Stroke Cerebrovasc Dis，2011，20（2）：134-144.
[20] MODI J，MENZIE-SUDERAM J，XU H，et al. Mode of action of granulocyte-colony stimulating factor（G-CSF）as a novel therapy for stroke in a mouse model[J/OL]. J Biomed Sci，2020，27（1）：19[2022-11-10]. https://doi. org/10.1186/s12929-019-0597-7.
[21] ZENG J，WANG Y，LUO Z，et al. TRIM9-mediated resolution of neuroinflammation confers neuroprotection upon ischemic stroke in mice[J]. Cell Rep，2019，27（2）：549-560.
[22] QIU L N，SUN Y，WANG L，et al. Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel[J/OL]. Eur J Pharmacol，2015，747：29-35[2022-11-10]. https://doi.org/10.1016/j.ejphar. 2014.11.037.
[23] YI X Y，WANG C，ZHOU Q，et al. Interaction among COX-2，P2Y1 and GPIIIa gene variants is associated with aspirin resistance and early neurological deterioration in Chinese stroke patients[J/OL]. BMC Neurol，2017，17：4[2022-11-10]. https://doi. org/10.1186/s12883-016-0788-8.
[24] PAN Y S，CHEN W Q，WANG Y L，et al. Association between ABCB1 polymorphisms and outcomes of clopidogrel treatment in patients with minor stroke or transient ischemic attack[J]. JAMA Neurol，2019，76（5）：552-560.
[25] CAMPO G，MICCOLI M，TEBALDI M，et al. Genetic determinants of on-clopidogrel high platelet reactivity[J]. Platelets，2011，22（6）：399-407.
[26] JOO H J，AHN S G，PARK J H，et al. Effects of genetic variants on platelet reactivity and one-year clinical outcomes after percutaneous coronary intervention：a prospective multicentre registry study[J/OL]. Sci Rep，2018，8（1）：1229[2022-11-10]. https://doi.org/10.1038/s41598-017-18134-y.
[27] PAN Y S，CHEN W Q，XU Y，et al. Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack[J]. Circulation，2017，135（1）：21-33.